Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

PHASE3TerminatedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

October 1, 2007

Primary Completion Date

February 12, 2009

Study Completion Date

February 12, 2009

Conditions
Alzheimer's Disease
Interventions
DRUG

Rosiglitazone XR

experimental drug

Trial Locations (70)

1113

GSK Investigational Site, Sofia

1431

GSK Investigational Site, Sofia

1527

GSK Investigational Site, Sofia

1600

GSK Investigational Site, Pasig

4000

GSK Investigational Site, Plovdiv

6725

GSK Investigational Site, Szeged

7623

GSK Investigational Site, Pécs

10000

GSK Investigational Site, Zagreb

10138

GSK Investigational Site, Tallinn

10614

GSK Investigational Site, Tallinn

10617

GSK Investigational Site, Tallinn

12163

GSK Investigational Site, Berlin

12167

GSK Investigational Site, Berlin

13507

GSK Investigational Site, Berlin

14000

GSK Investigational Site, México

19053

GSK Investigational Site, Schwerin

19055

GSK Investigational Site, Schwerin

20249

GSK Investigational Site, Hamburg

22083

GSK Investigational Site, Hamburg

25000

GSK Investigational Site, Saltillo

28832

GSK Investigational Site, Achim

30559

GSK Investigational Site, Hanover

32901

GSK Investigational Site, Melbourne

33016

GSK Investigational Site, Hialeah

33064

GSK Investigational Site, Deerfield Beach

33317

GSK Investigational Site, Plantation

33613

GSK Investigational Site, Tampa

37212

GSK Investigational Site, Nashville

44892

GSK Investigational Site, Bochum

45459

GSK Investigational Site, Centerville

47051

GSK Investigational Site, Duisburg

50767

GSK Investigational Site, Cologne

51014

GSK Investigational Site, Tartu

52428

GSK Investigational Site, Jülich

52499

GSK Investigational Site, Baesweiler

57010

GSK Investigational Site, Thessaloniki

61348

GSK Investigational Site, Bad Homburg

64660

GSK Investigational Site, Monterrey

72076

GSK Investigational Site, Tübingen

73479

GSK Investigational Site, Ellwangen

74104

GSK Investigational Site, Tulsa

80331

GSK Investigational Site, Munich

82008

GSK Investigational Site, Unterhaching

89312

GSK Investigational Site, Günzburg

90402

GSK Investigational Site, Nuremberg

94305

GSK Investigational Site, Palo Alto

100083

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

115522

GSK Investigational Site, Moscow

117049

GSK Investigational Site, Moscow

198103

GSK Investigational Site, Saint Petersburg

200025

GSK Investigational Site, Shanghai

200030

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

300052

GSK Investigational Site, Tianjin

510370

GSK Investigational Site, Guangzhou

7500710

GSK Investigational Site, Santiago

7560356

GSK Investigational Site, Santiago

A-8020

GSK Investigational Site, Graz-Eggenberg

A-6060

GSK Investigational Site, Hall in Tirol

252-0997

GSK Investigational Site, Viña del Mar

01097

GSK Investigational Site, Dresden

01307

GSK Investigational Site, Dresden

115 21

GSK Investigational Site, Athens

0622

GSK Investigational Site, Auckland

Lima 13

GSK Investigational Site, Lima

00918

GSK Investigational Site, San Juan

463-707

GSK Investigational Site, Seongnam-si

143-729

GSK Investigational Site, Seoul

G20 0XA

GSK Investigational Site, West of Scotland Science Park, Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY